Anaptysbio (ANAB) Common Equity (2016 - 2026)

Anaptysbio's Common Equity history runs 11 years deep, the most recent figure standing at $12.7 million for Q1 2026.

• Quarterly Common Equity fell 62.53% year-over-year to $12.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.7 million (down 62.53% YoY) and the FY2025 annual result came in at $37.2 million, down 47.49% from the prior year.
• Common Equity was $12.7 million for Q1 2026 at Anaptysbio, down from $37.2 million in the prior quarter.
• Across five years, Common Equity topped out at $330.7 million in Q1 2022 and bottomed at -$44.7 million in Q2 2025.
• A 5-year average of $114.4 million and a median of $84.4 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity retreated 13.4% — and 2025, when it plunged 552.81%.
• Anaptysbio's Common Equity stood at $262.1 million in 2022, then plunged by 66.39% to $88.1 million in 2023, then retreated by 19.56% to $70.9 million in 2024, then sank by 47.49% to $37.2 million in 2025, then sank by 65.74% to $12.7 million in 2026.
• Business Quant data shows ANAB's Common Equity at $12.7 million in Q1 2026, $37.2 million in Q4 2025, and -$29.4 million in Q3 2025.